IMDX
NASDAQ · Biotechnology
Insight Molecular Diagnostic
$7.32
+0.63 (+9.42%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.94M | 22.03M | 22.77M |
| Net Income | 4.47M | 4.29M | 5.70M |
| EPS | — | — | — |
| Profit Margin | 20.4% | 19.5% | 25.1% |
| Rev Growth | -4.7% | +9.7% | +22.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 100.39M | 89.77M | 100.88M |
| Total Equity | 98.71M | 88.43M | 94.78M |
| D/E Ratio | 1.02 | 1.02 | 1.06 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 9.15M | 9.08M | 9.52M |
| Free Cash Flow | 3.10M | 3.08M | 2.32M |